- Wednesday, June 21, 2023
8:00 AM – 8:15 AM
Welcome
8:00 AM – 8:15 AM
WelcomeCo-Chair: – Weill Cornell Medicine/New York Presbyterian
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Co-Chair###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Co-Chair: – Weill Cornell Medicine/New York Presbyterian
### 8:15 AM – 9:00 AM
1 - Session 1: Choosing among Options for the Initial Therapy of Aggressive Lymphoma
8:15 AM – 9:00 AM
Session 1: Choosing among Options for the Initial Therapy of Aggressive LymphomaPresenter: – Weill Cornell Medicine/New York Presbyterian
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Presenter###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Presenter: – Weill Cornell Medicine/New York Presbyterian
### 9:00 AM – 9:15 AM
Break
9:15 AM – 10:00 AM
Session 2: Quality of Life and Survivorship in Lymphoma Patient
9:15 AM – 10:00 AM
Session 2: Quality of Life and Survivorship in Lymphoma Patient
Carrie Thompson, MD, MS – Mayo Clinic ### 1649998###Presenter###Associate Professor###Mayo Clinic###Presenter: – Mayo Clinic
### 10:00 AM – 10:15 AM
Break
10:00 AM – 10:15 AM
Break
10:15 AM – 11:15 AM
Learn About a Different Approach to BTK Inhibition PP-PT-US-0216
10:15 AM – 11:15 AM
Non-CME Innovation Theater - Sponsored by Lilly
11:15 AM – 11:30 AM
Break
11:15 AM – 11:30 AM
Break
11:30 AM – 12:05 PM
4 - Session 3: How Do We Choose among non-CAR-T Options for Patients with Recurrent Aggressive LymphomaPresenter: – Columbia University
11:30 AM – 12:05 PM
Session 3: How Do We Choose among non-CAR-T Options for Patients with Recurrent Aggressive LymphomaPresenter: – Columbia University
Jennifer Amengual, MD – Columbia University ### 1221874###Presenter###Herbert Irving Assistant Professor of Medicine###Columbia University###Presenter: – Columbia University
### 12:05 PM – 12:15 PM
Live Q&AModerator: – Weill Cornell Medicine/New York Presbyterian
Speaker: – Columbia University
12:05 PM – 12:15 PM
Live Q&AModerator: – Weill Cornell Medicine/New York Presbyterian
Speaker: – Columbia University
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Moderator###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Moderator: – Weill Cornell Medicine/New York Presbyterian
### @@@ Jennifer Amengual, MD – Columbia University ### 1221874###Speaker###Herbert Irving Assistant Professor of Medicine###Columbia University###Speaker: – Columbia University
### 12:15 PM – 12:30 PM
Break
12:15 PM – 12:30 PM
Break
12:30 PM – 1:05 PM
Session 4: Arguments For and Against ‘Watch and Wait’ in Follicular Lymphoma
12:30 PM – 1:05 PM
Session 4: Arguments For and Against ‘Watch and Wait’ in Follicular LymphomaPresenter: – Dana-Farber Cancer Institute
Ann LaCasce, MD – Dana-Farber Cancer Institute ### 1364718###Presenter###Associate Professor of Medicine###Dana-Farber Cancer Institute###Presenter: – Dana-Farber Cancer Institute
### 1:05 PM – 1:15 PM
Live Q&A
1:05 PM – 1:15 PM
Live Q&AModerator: – Weill Cornell Medicine/New York Presbyterian
Speaker: – Dana-Farber Cancer Institute
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Moderator###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Moderator: – Weill Cornell Medicine/New York Presbyterian
### @@@ Ann LaCasce, MD – Dana-Farber Cancer Institute ### 1364718###Speaker###Associate Professor of Medicine###Dana-Farber Cancer Institute###Speaker: – Dana-Farber Cancer Institute
### 1:15 PM – 1:30 PM
Break
1:30 PM – 2:05 PM
5 - Session 5: Antibody Drug Conjugates – Where and When to Use Them in Hodgkin Lymphoma
1:30 PM – 2:05 PM
Session 5: Antibody Drug Conjugates – Where and When to Use Them in Hodgkin LymphomaPresenter: – Rutgers University
Andrew Evens, DO, MBA, MSc (he/him/his) – Rutgers University ### 1649997###Presenter###Associate Vice Chancellor, RBHS, and Associate Director, Rutgers CINJ###Rutgers University###Presenter: – Rutgers University
### he/him/his2:05 PM – 2:15 PM
Live Q&A
2:05 PM – 2:15 PM
Live Q&AModerator: – Weill Cornell Medicine/New York Presbyterian
Speaker: – Rutgers University
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Moderator###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Moderator: – Weill Cornell Medicine/New York Presbyterian
### @@@ Andrew Evens, DO, MBA, MSc (he/him/his) – Rutgers University ### 1649997###Speaker###Associate Vice Chancellor, RBHS, and Associate Director, Rutgers CINJ###Rutgers University###Speaker: – Rutgers University
### he/him/his2:15 PM – 2:30 PM
Break
2:30 PM – 3:05 PM
Session 6: What is the Value of Surveillance Imaging in Aggressive Lymphoma and How Can We Tailor Follow Up?Presenter: – NewYork Presbyterian Hospital, Weill Cornell Medicine
2:30 PM – 3:05 PM
Session 6: What is the Value of Surveillance Imaging in Aggressive Lymphoma and How Can We Tailor Follow Up?Presenter: – NewYork Presbyterian Hospital, Weill Cornell Medicine
Peter Martin, MD – NewYork Presbyterian Hospital, Weill Cornell Medicine ### 701594###Presenter###Associate Professor of Medicine###NewYork Presbyterian Hospital, Weill Cornell Medicine###Presenter: – NewYork Presbyterian Hospital, Weill Cornell Medicine
### 3:05 PM – 3:15 PM
Live Q&AModerator: – Weill Cornell Medicine/New York Presbyterian
Speaker: – NewYork Presbyterian Hospital, Weill Cornell Medicine
3:05 PM – 3:15 PM
Live Q&AModerator: – Weill Cornell Medicine/New York Presbyterian
Speaker: – NewYork Presbyterian Hospital, Weill Cornell Medicine
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Moderator###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Moderator: – Weill Cornell Medicine/New York Presbyterian
### @@@ Peter Martin, MD – NewYork Presbyterian Hospital, Weill Cornell Medicine ### 701594###Speaker###Associate Professor of Medicine###NewYork Presbyterian Hospital, Weill Cornell Medicine###Speaker: – NewYork Presbyterian Hospital, Weill Cornell Medicine
### 3:15 PM – 3:30 PM
Break
3:30 PM – 3:47 PM
7 - Session 7: Debate - CNS Prophylaxis in Aggressive Lymphoma - Aggressive
3:30 PM – 3:47 PM
Session 7: Debate - CNS Prophylaxis in Aggressive Lymphoma - AggressivePresenter: – Alpert Medical School of Brown University
Adam J. Olszewski, MD – Alpert Medical School of Brown University ### 1630531###Presenter###Associate Professor of Medicine###Alpert Medical School of Brown University###Presenter: – Alpert Medical School of Brown University
### 3:47 PM – 4:05 PM
7 - Session 7: Debate - CNS Prophylaxis in Aggressive Lymphoma - Futile
3:47 PM – 4:05 PM
Session 7: Debate - CNS Prophylaxis in Aggressive Lymphoma - FutilePresenter: – Chao Family Comprehensive Cancer Center, University of California, Irvine
Elizabeth A. Brem, MD (she/her/hers) – Chao Family Comprehensive Cancer Center, University of California, Irvine ### 694303###Presenter###Clinical Associate Professor###Chao Family Comprehensive Cancer Center, University of California, Irvine###Presenter: – Chao Family Comprehensive Cancer Center, University of California, Irvine
### she/her/hers4:05 PM – 4:15 PM
7 - Session 7: Debate - CNS Prophylaxis in Aggressive Lymphoma
4:05 PM – 4:15 PM
Session 7: Debate - CNS Prophylaxis in Aggressive Lymphoma - DiscussionModerator: – Weill Cornell Medicine/New York Presbyterian
Panelist: – Alpert Medical School of Brown University
Panelist: – Chao Family Comprehensive Cancer Center, University of California, Irvine
John P. Leonard, MD – Weill Cornell Medicine/New York Presbyterian ### 692254###Moderator###Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology###Weill Cornell Medicine/New York Presbyterian###Moderator: – Weill Cornell Medicine/New York Presbyterian
### @@@ Adam J. Olszewski, MD – Alpert Medical School of Brown University ### 1630531###Panelist###Associate Professor of Medicine###Alpert Medical School of Brown University###Panelist: – Alpert Medical School of Brown University
### @@@ Elizabeth A. Brem, MD (she/her/hers) – Chao Family Comprehensive Cancer Center, University of California, Irvine ### 694303###Panelist###Clinical Associate Professor###Chao Family Comprehensive Cancer Center, University of California, Irvine###Panelist: – Chao Family Comprehensive Cancer Center, University of California, Irvine
### she/her/hers- Thursday, June 22, 2023
8:00 AM – 8:15 AM
Welcome
8:00 AM – 8:15 AM
WelcomeCo-Chair: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Co-Chair###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Co-Chair: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### 8:15 AM – 8:50 AM
8 - Session 8: Exciting Advances in MyelofibrosisPresenter: – Icahn School of Medicine at Mount Sinai
8:15 AM – 8:50 AM
Session 8: Exciting Advances in MyelofibrosisPresenter: – Icahn School of Medicine at Mount Sinai
John O. Mascarenhas, MD – Icahn School of Medicine at Mount Sinai ### 972510###Presenter### Professor of Medicine ###Icahn School of Medicine at Mount Sinai ###Presenter: – Icahn School of Medicine at Mount Sinai
### 8:50 AM – 9:00 AM
Live Q&AModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Speaker: – Icahn School of Medicine at Mount Sinai
8:50 AM – 9:00 AM
Live Q&AModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Speaker: – Icahn School of Medicine at Mount Sinai
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Moderator###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Moderator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### @@@ John O. Mascarenhas, MD – Icahn School of Medicine at Mount Sinai ### 972510###Speaker### Professor of Medicine ###Icahn School of Medicine at Mount Sinai ###Speaker: – Icahn School of Medicine at Mount Sinai
### 9:00 AM – 9:15 AM
Break
9:15 AM – 9:50 AM
9 - Session 9: First Line Treatment of CLL/SLL with Bruton 's Tyrosine Kinase Inhibitors: Seeking Lasting Results
9:15 AM – 9:50 AM
Session 9: First Line Treatment of CLL/SLL with Bruton 's Tyrosine Kinase Inhibitors: Seeking Lasting ResultsPresenter: – Weill Cornell Medicine
John N. Allan, MD – Weill Cornell Medicine ### 748659###Presenter###Associate Professor of Clinical Medicine###Weill Cornell Medicine###Presenter: – Weill Cornell Medicine
### 9:50 AM – 10:00 AM
Live Q&A
9:50 AM – 10:00 AM
Live Q&AModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Speaker: – Weill Cornell Medicine
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Moderator###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Moderator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### @@@ John N. Allan, MD – Weill Cornell Medicine ### 748659###Speaker###Associate Professor of Clinical Medicine###Weill Cornell Medicine###Speaker: – Weill Cornell Medicine
### 10:00 AM – 10:15 AM
Break
10:00 AM – 10:15 AM
Break
10:15 AM – 11:15 AM
REZLIDHIA: Induce Durable Complete Remissions in Adult Patients with Relapsed/Refractory mIDH1 AML
10:15 AM – 11:15 AM
Non-CME Innovation Theater - Sponsored by Rigel
11:15 AM – 11:30 AM
Break
11:15 AM – 11:30 AM
Break
11:30 AM – 12:05 PM
10 - Session 10: What Are the Latest Strategies for Relapsed CLL and What Is on the Horizon?
11:30 AM – 12:05 PM
Session 10: What Are the Latest Strategies for Relapsed CLL and What Is on the Horizon?Presenter: – Dana-Farber Cancer Institute; Harvard Medical School
Jennifer R. Brown, MD, PhD (she/her/hers) – Dana-Farber Cancer Institute; Harvard Medical School ### 748664###Presenter###Director, CLL Center & Institute Physician; Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology###Dana-Farber Cancer Institute; Harvard Medical School###Presenter: – Dana-Farber Cancer Institute; Harvard Medical School
### she/her/hers12:05 PM – 12:15 PM
10 - Live Q&A
12:05 PM – 12:15 PM
Live Q&AModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Speaker: – Dana-Farber Cancer Institute; Harvard Medical School
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Moderator###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Moderator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### @@@ Jennifer R. Brown, MD, PhD (she/her/hers) – Dana-Farber Cancer Institute; Harvard Medical School ### 748664###Speaker###Director, CLL Center & Institute Physician; Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology###Dana-Farber Cancer Institute; Harvard Medical School###Speaker: – Dana-Farber Cancer Institute; Harvard Medical School
### she/her/hers12:15 PM – 12:30 PM
Break
12:15 PM – 12:30 PM
Break
12:30 PM – 1:15 PM
Session 11: Where Are We with CAR-T in ALL and AML Today and What Does the Future Look Like?Presenter: – Memorial Sloan Kettering Cancer Center
12:30 PM – 1:15 PM
Session 11: Where Are We with CAR-T in ALL and AML Today and What Does the Future Look Like?Presenter: – Memorial Sloan Kettering Cancer Center
Jae Park, MD – Memorial Sloan Kettering Cancer Center ### 879265###Presenter###Associate Attending Physician###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 1:15 PM – 1:30 PM
Break
1:30 PM – 2:05 PM
11 - Session 12: Effective Risk Stratification and Expert Treatment Selection Advice for Patients with Myelodysplastic Syndromes
1:30 PM – 2:05 PM
Session 12: Effective Risk Stratification and Expert Treatment Selection Advice for Patients with Myelodysplastic SyndromesPresenter: – Yale New Haven Health
Amer M. Zeidan, MBBS, MHS (he/him/his) – Yale New Haven Health ### 703522###Presenter###Associate Professor###Yale New Haven Health###Presenter: – Yale New Haven Health
### he/him/his2:05 PM – 2:15 PM
Live Q&A
2:05 PM – 2:15 PM
Live Q&AModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Speaker: – Yale New Haven Health
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Moderator###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Moderator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### @@@ Amer M. Zeidan, MBBS, MHS (he/him/his) – Yale New Haven Health ### 703522###Speaker###Associate Professor###Yale New Haven Health###Speaker: – Yale New Haven Health
### he/him/his2:15 PM – 2:30 PM
Break
2:30 PM – 3:15 PM
12 - Session 13: Case Discussions in AML, MDS and ALLModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Panelist: – Northwestern University
Panelist: – Yale New Haven Health
2:30 PM – 3:15 PM
Session 13: Case Discussions in AML, MDS and ALLModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Panelist: – Northwestern University
Panelist: – Yale New Haven Health
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Moderator###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Moderator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### @@@ Shira Dinner, MD – Northwestern University ### 1186958###Panelist###Associate Professor###Northwestern University###Panelist: – Northwestern University
### @@@ Amer M. Zeidan, MBBS, MHS (he/him/his) – Yale New Haven Health ### 703522###Panelist###Associate Professor###Yale New Haven Health###Panelist: – Yale New Haven Health
### he/him/his3:15 PM – 3:30 PM
Break
3:30 PM – 3:47 PM
14 - Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - Yes
3:30 PM – 3:47 PM
Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - YesPresenter: – City of Hope
Andrew Artz, MD, MS – City of Hope ### 1649062###Presenter###Professor###City of Hope###Presenter: – City of Hope
### 3:47 PM – 4:05 PM
14 - Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - No
3:47 PM – 4:05 PM
Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - NoPresenter: – Dana-Farber Cancer Institute, Harvard Medical School
Richard M. Stone, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 972507###Presenter###Chief of Staff; Professor of Medicine###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his4:05 PM – 4:15 PM
14 - Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT
4:05 PM – 4:15 PM
Session 14: Debate - MRD+ Patients with AML Should Proceed with HSCT - DiscussionModerator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
Panelist: – City of Hope
Panelist: – Dana-Farber Cancer Institute, Harvard Medical School
Jessica K. Altman, MD – Robert H. Lurie Comprehensive Cancer Center; Northwestern University ### 944495###Moderator###Professor of Medicine###Robert H. Lurie Comprehensive Cancer Center; Northwestern University###Moderator: – Robert H. Lurie Comprehensive Cancer Center; Northwestern University
### @@@ Andrew Artz, MD, MS – City of Hope ### 1649062###Panelist###Professor###City of Hope###Panelist: – City of Hope
### @@@ Richard M. Stone, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 972507###Panelist###Chief of Staff; Professor of Medicine###Dana-Farber Cancer Institute, Harvard Medical School###Panelist: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his- Friday, June 23, 2023
8:00 AM – 8:15 AM
Welcome
8:00 AM – 8:15 AM
Welcome
8:15 AM – 8:32 PM
15 - Session 15: Debate - Will ASCT Continue to Be the Standard of Care in Frontline Therapy? - Yes
8:15 AM – 8:32 PM
Session 15: Debate - Will ASCT Continue to Be the Standard of Care in Frontline Therapy? - YesPresenter: – City of Hope Comprehensive Cancer Center
Amrita Y. Krishnan, MD, FACP – City of Hope Comprehensive Cancer Center ### 902613###Presenter###Director of Judy and Bernard Briskin Center for Multiple Myeloma###City of Hope Comprehensive Cancer Center###Presenter: – City of Hope Comprehensive Cancer Center
### 8:32 AM – 8:50 AM
15 - Session 15: Debate - Will ASCT Continue to Be the Standard of Care in Frontline Therapy? - No
8:32 AM – 8:50 AM
Session 15: Debate - Will ASCT Continue to Be the Standard of Care in Frontline Therapy? - NoPresenter: – Sylvester Comprehensive Cancer Center, University of Miami
C. Ola Landgren, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami ### 1364707###Presenter###Professor of Medicine; Chief of Myeloma Division; Director of Sylvester Myeloma Research Institute; Leader of Experimental Therapeutics Program###Sylvester Comprehensive Cancer Center, University of Miami###Presenter: – Sylvester Comprehensive Cancer Center, University of Miami
### 8:49 AM – 9:00 AM
15 - Session 15: Debate - Will ASCT Continue to Be the Standard of Care in Frontline Therapy?
8:49 AM – 9:00 AM
Session 15: Debate - Will ASCT Continue to Be the Standard of Care in Frontline Therapy? - DiscussionModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Panelist: – City of Hope Comprehensive Cancer Center
Panelist: – Sylvester Comprehensive Cancer Center, University of Miami
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Moderator###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Moderator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### @@@ Amrita Y. Krishnan, MD, FACP – City of Hope Comprehensive Cancer Center ### 902613###Panelist###Director of Judy and Bernard Briskin Center for Multiple Myeloma###City of Hope Comprehensive Cancer Center###Panelist: – City of Hope Comprehensive Cancer Center
### @@@ C. Ola Landgren, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami ### 1364707###Panelist###Professor of Medicine; Chief of Myeloma Division; Director of Sylvester Myeloma Research Institute; Leader of Experimental Therapeutics Program###Sylvester Comprehensive Cancer Center, University of Miami###Panelist: – Sylvester Comprehensive Cancer Center, University of Miami
### 9:00 AM – 9:15 AM
Break
9:15 AM – 9:50 AM
16 - Session 16: Optimal Frontline Therapy of Myeloma
9:15 AM – 9:50 AM
Session 16: Optimal Frontline Therapy of MyelomaPresenter: – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine
Peter M. Voorhees, MD – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine ### 903003###Presenter###Clinical Professor of Medicine###Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine###Presenter: – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine
### 9:50 AM – 10:00 AM
Live Q&A
9:50 AM – 10:00 AM
Live Q&AModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Speaker: – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Moderator###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Moderator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### @@@ Peter M. Voorhees, MD – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine ### 903003###Speaker###Clinical Professor of Medicine###Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine###Speaker: – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine
### 10:00 AM – 10:15 AM
Break
10:00 AM – 10:15 AM
Break
10:15 AM – 11:15 AM
Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types
10:15 AM – 11:15 AM
Non-CME Innovation Theater - Sponsored by Janssen
11:15 AM – 11:30 AM
Break
11:15 AM – 11:30 AM
Break
11:30 AM – 12:05 PM
20 - Session 17: Making Sense of the Choices in Relapsed Myeloma
11:30 AM – 12:05 PM
Session 17: Making Sense of the Choices in Relapsed MyelomaPresenter: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Presenter###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Presenter: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### 12:05 PM – 12:15 PM
Live Q&A
12:05 PM – 12:15 PM
Live Q&ASpeaker: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Panelist: – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Speaker###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Speaker: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### @@@ Peter M. Voorhees, MD – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine ### 903003###Panelist###Clinical Professor of Medicine###Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine###Panelist: – Levine Cancer Institute, Atrium Health / Wake Forest School of Medicine
### 12:15 PM – 12:30 PM
Break
12:15 PM – 12:30 PM
Break
12:30 PM – 1:05 PM
19 - Session 18: Relapsed/ Refractory Multiple Myeloma: Novel and Cellular Therapies in 2023Presenter: – Memorial Sloan Kettering Cancer Center
12:30 PM – 1:05 PM
Session 18: Relapsed/ Refractory Multiple Myeloma: Novel and Cellular Therapies in 2023Presenter: – Memorial Sloan Kettering Cancer Center
Saad Z. Usmani, MD, MBA, FACP – Memorial Sloan Kettering Cancer Center ### 690123###Presenter###Chief of Myeloma Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 1:05 PM – 1:15 PM
Live Q&AModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Speaker: – Memorial Sloan Kettering Cancer Center
1:05 PM – 1:15 PM
Live Q&AModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Speaker: – Memorial Sloan Kettering Cancer Center
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Moderator###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Moderator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### @@@ Saad Z. Usmani, MD, MBA, FACP – Memorial Sloan Kettering Cancer Center ### 690123###Speaker###Chief of Myeloma Service###Memorial Sloan Kettering Cancer Center###Speaker: – Memorial Sloan Kettering Cancer Center
### 1:15 PM – 1:30 PM
Break
1:30 PM – 2:15 PM
Session 19: The Future of MyelomaPresenter: – UCSF Medical Center
1:30 PM – 2:15 PM
Session 19: The Future of MyelomaPresenter: – UCSF Medical Center
Thomas G. Martin, MD – UCSF Medical Center ### 972492###Presenter###Clinical Professor of Medicine###UCSF Medical Center###Presenter: – UCSF Medical Center
### 2:15 PM – 2:30 PM
Break
2:30 PM – 3:05 PM
Session 20: Health Disparity in MM and How to Overcome It in the ClinicPresenter: – Michigan State University College of Human Medicine-Karmanos Cancer Institute
2:30 PM – 3:05 PM
Session 20: Health Disparity in MM and How to Overcome It in the ClinicPresenter: – Michigan State University College of Human Medicine-Karmanos Cancer Institute
Craig Emmitt Cole, MD (he/him/his) – Michigan State University College of Human Medicine-Karmanos Cancer Institute ### 1836897###Presenter###Assistant Professor Director of Clinical Research###Michigan State University College of Human Medicine-Karmanos Cancer Institute ###Presenter: – Michigan State University College of Human Medicine-Karmanos Cancer Institute
### he/him/his3:05 PM – 3:15 PM
Live Q&AModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Speaker: – Michigan State University College of Human Medicine-Karmanos Cancer Institute
3:05 PM – 3:15 PM
Live Q&AModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Speaker: – Michigan State University College of Human Medicine-Karmanos Cancer Institute
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Moderator###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Moderator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### @@@ Craig Emmitt Cole, MD (he/him/his) – Michigan State University College of Human Medicine-Karmanos Cancer Institute ### 1836897###Speaker###Assistant Professor Director of Clinical Research###Michigan State University College of Human Medicine-Karmanos Cancer Institute ###Speaker: – Michigan State University College of Human Medicine-Karmanos Cancer Institute
### he/him/his3:15 PM – 3:30 PM
Break
3:30 PM – 4:05 PM
21 - Session 21: How Do I Diagnose and Treat AL Amyloidosis?
3:30 PM – 4:05 PM
Session 21: How Do I Diagnose and Treat AL Amyloidosis?Presenter: – City of Hope
Michael Rosenzweig, MD – City of Hope ### 1830638###Presenter###Associate Professor of Medicine###City of Hope###Presenter: – City of Hope
### 4:05 PM – 4:15 PM
Live Q&A
4:05 PM – 4:15 PM
Live Q&AModerator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Speaker: – City of Hope
Joseph Mikhael, MD, MEd, FRCPC, FACP – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 683990###Moderator###Professor###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###Moderator: – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
### @@@ Michael Rosenzweig, MD – City of Hope ### 1830638###Speaker###Associate Professor of Medicine###City of Hope###Speaker: – City of Hope
### - On-Demand
45 minutes
Chemo-free or Chemo-light Approaches to the Treatment of ALL?Presenter: – Northwestern University
45 minutes
Chemo-free or Chemo-light Approaches to the Treatment of ALL?Presenter: – Northwestern University
Shira Dinner, MD – Northwestern University ### 1186958###Presenter###Associate Professor###Northwestern University###Presenter: – Northwestern University
### 45 minutes
Help! Making Sense of the ICC/ELN Classifications and Where Do They Fit with the WHO? What Should the Practicing Hematologist/Oncologist Be Aware Of?Presenter: – MD Anderson Cancer Center
45 minutes
Help! Making Sense of the ICC/ELN Classifications and Where Do They Fit with the WHO? What Should the Practicing Hematologist/Oncologist Be Aware Of?Presenter: – MD Anderson Cancer Center
Sanam Loghavi, MD – MD Anderson Cancer Center ### 1836898###Presenter###Associate Professor ###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 45 minutes
45 minutes
Mrinal M. Patnaik, MD – Mayo Clinic ### 1187163###Presenter###Professor of Internal Medicine, Division of Hematology###Mayo Clinic###Presenter: – Mayo Clinic
### 45 minutes
What is the Future of ctDNA in Lymphoma?
45 minutes
What is the Future of ctDNA in Lymphoma?
Mark Roschewski, MD – Center for Cancer Research, National Cancer Institute ### 1836896###Presenter###Clinical Director###Center for Cancer Research, National Cancer Institute###Presenter: – Center for Cancer Research, National Cancer Institute
###
